Page last updated: 2024-12-05
chlorthenoxazin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
chlorthenoxazin: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 8602 |
| CHEMBL ID | 124815 |
| CHEBI ID | 134882 |
| SCHEMBL ID | 25595 |
| MeSH ID | M0049957 |
Synonyms (74)
| Synonym |
|---|
| reugaril |
| 4-oxo-2-(beta-chloroethyl)-2,3-dihydrobenzo-1,3-oxazine |
| chlorthenoxazine [inn] |
| chlorthenoxazinum [inn-latin] |
| brn 0170863 |
| einecs 205-082-3 |
| 4h-1,3-benzoxazin-4-one, 2-(2-chloroethyl)-2,3-dihydro- |
| 2-(2-chloroethyl)-2,3-dihydro-4-oxo-1,3-benzoxazine |
| 2-(beta-chloroethyl)-2,3-dihydro-4-oxo(benzo-1,3-oxazine) |
| nsc 525254 |
| 2-(2-chloroethyl)-2,3-dihydro-4h-1,3-benzoxazin-4-one |
| clortenoxazina [inn-spanish] |
| betix |
| ossipirina |
| ossazone |
| reulin |
| wln: t66 bvm eo dhj d2g |
| reumagrip |
| nsc-525254 |
| 2-(2-chloroethyl)-3-aza-4-chromanone |
| 2-(2-chloroethyl)-2,3-benzoxazin-4-one |
| 2-(2-chloroethyl)-2,3-benzoxazine |
| valtorin |
| apirazin |
| 4h-1, 2-(2-chloroethyl)-2,3-dihydro- |
| chlorthenoxazine |
| valmorin |
| 2-(.beta.-chloroethyl)-2,3-oxazine) |
| 132-89-8 |
| nsc525254 |
| 4-oxo-2-(.beta.-chloroethyl)-2,3-oxazine |
| chlorethylbenzmethoxazone |
| ap 67 |
| chlorthenoxazin |
| CHEBI:134882 |
| 2-(2-chloroethyl)-2,3-dihydro-1,3-benzoxazin-4-one |
| CHEMBL124815 , |
| ap-67 |
| benzmethoxazone |
| piroxina |
| chlorthenoxazin(e) |
| bdbm50106191 |
| 2-(2-chloro-ethyl)-2,3-dihydro-benzo[e][1,3]oxazin-4-one (chlorthenoxazin) |
| 4h-1,3-benzoxazin-4-one, 2,3-dihydro-2-(2-chloroethyl)- |
| niosh/dm3743000 |
| DM37430000 |
| 2-(2-chloroethyl)-2h-1,3-benzoxazin-4(3h)-one |
| chlorthenoxazinum |
| chlorthenoxazine [inn:ban] |
| ka0b657lv3 , |
| clortenoxazina |
| 4-27-00-02766 (beilstein handbook reference) |
| unii-ka0b657lv3 |
| chlorthenoxazine [who-dd] |
| chlorthenoxazine [mart.] |
| chlorthenoxazin(e) [mi] |
| SCHEMBL25595 |
| 2-(beta-chlorathyl)-2,3-dihydro-4-oxobenz-1,3-oxazin |
| 2-(.beta.-chloroethyl)-2,3-dihydro-4-oxo(benzo-1,3-oxazine) |
| component of fiobrol (salt/mix) |
| ossapirina |
| component of trigatan (salt/mix) |
| YEKMWXFHPZBZLR-UHFFFAOYSA-N |
| 4-oxo-2-(.beta.-chloroethyl)-2,3-dihydrobenzo-1,3-oxazine |
| 2-(2-chloroethyl)-2h-benzo[e][1,3]oxazin-4(3h)-one |
| HY-101751 |
| CS-6577 |
| Z1269198910 |
| DTXSID70861786 |
| AKOS034122341 |
| Q27282145 |
| EX-A4522 |
| 2-(2-chloroethyl)-3,4-dihydro-2h-1,3-benzoxazin-4-one |
| EN300-257452 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| benzoxazine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | IC50 (µMol) | 8.5000 | 0.0002 | 0.8123 | 9.8100 | AID154621 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (56)
Molecular Functions (30)
Ceullar Components (16)
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID493017 | Wombat Data for BeliefDocking | 2001 | Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23 | Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. |
| AID154621 | The compound was tested for poly(ADP-ribose)-polymerase (PARP) inhibition | 2001 | Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23 | Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||